Discover
Zejula (niraparib) / GSK, ZAI Lab, J&J, TakedaZai Lab announces positive topline results from the NORA phase 3 study of Zejula as maintenance therapy for chinese patients with platinum-sensitive, recurrent ovarian cancer (GlobeNewswire) - May 28, 2020 - P3, N=381; NORA (NCT03709316); Sponsor: Zai Lab (Shanghai) Co., Ltd; "Zai Lab Limited...announced positive topline results from the NORA study, the Phase 3 randomized, double-blind, placebo-controlled, study of ZEJULA (niraparib) as a maintenance therapy in Chinese patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer (collectively termed as ovarian cancer) who are in a complete or partial response to platinum-based chemotherapy....The study met its primary endpoint of a statistically significant improvement in progression free survival for patients with ovarian cancer regardless of their biomarker status. The safety profile was consistent with what was observed from the global NOVA study with lower rates of anemia and thrombocytopenia."
AsiDNA (etidaligide) / Onxeo; Zejula (niraparib) / GSK, ZAI Lab, J&J, TakedaOnxeo announces approval of the REVocan study by regulatory authorities (GlobeNewswire) - May 29, 2020 - "Onxeo S.A...announced that the REVocan1 phase 1b/2 designed to evaluate the effect of AsiDNA™, Onxeo’s first-in-class DDR inhibitor, on the acquired resistance to PARP inhibitor (PARPi) niraparib for 2nd line maintenance treatment of relapsed ovarian cancer, has received approval from the French National Agency for the Safety of Medicines and Health Products (ANSM) and the Ethics Committee (CPP)....The first patients could be recruited as early as the third quarter of 2020, with the aim of obtaining preliminary results at the end of 2020 or early in 2021."
Bavencio (avelumab) / EMD Serono, Pfizer; Talzenna (talazoparib) / PfizerJavelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors (clinicaltrials.gov) - May 27, 2020 - P1b/2; N=214; Active, not recruiting; Sponsor: Pfizer; Recruiting --> Active, not recruiting
